Champions Oncology, Inc.
CSBR
$5.26
-$0.20-3.66%
NASDAQ
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.84M | 16.56M | 15.04M | 14.00M | 12.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.84M | 16.56M | 15.04M | 14.00M | 12.36M |
| Cost of Revenue | 6.81M | 8.83M | 7.26M | 8.00M | 7.27M |
| Gross Profit | 7.03M | 7.73M | 7.77M | 6.00M | 5.08M |
| SG&A Expenses | 5.43M | 5.64M | 4.97M | 4.43M | 4.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.36M | 16.75M | 14.85M | 14.50M | 14.07M |
| Operating Income | -521.00K | -187.00K | 185.00K | -507.00K | -1.71M |
| Income Before Tax | -495.00K | -237.00K | 255.00K | -452.00K | -1.96M |
| Income Tax Expenses | 172.00K | 42.00K | 18.00K | 14.00K | -129.00K |
| Earnings from Continuing Operations | -667.00K | -279.00K | 237.00K | -466.00K | -1.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 31.00K | 30.00K | -- |
| Net Income | -667.00K | -279.00K | 268.00K | -436.00K | -1.84M |
| EBIT | -521.00K | -187.00K | 185.00K | -507.00K | -1.71M |
| EBITDA | -200.00K | 154.00K | 542.00K | -149.00K | -1.32M |
| EPS Basic | -0.05 | -0.02 | 0.02 | -0.03 | -0.13 |
| Normalized Basic EPS | -0.02 | -0.01 | 0.01 | -0.02 | -0.08 |
| EPS Diluted | -0.05 | -0.02 | 0.02 | -0.03 | -0.13 |
| Normalized Diluted EPS | -0.02 | -0.01 | 0.01 | -0.02 | -0.08 |
| Average Basic Shares Outstanding | 13.91M | 13.89M | 13.79M | 13.79M | 13.75M |
| Average Diluted Shares Outstanding | 13.91M | 13.89M | 14.46M | 13.79M | 13.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |